Market Overview

UPDATE: Bank of America Downgrades Dr. Reddy's Laboratories to Neutral on Modest Outlook

Share:
Related RDY
Credit Suisse Prescribes Underperform Rating For Dr. Reddy's With Drop In U.S. Sales
Benzinga's Weekend M&A Chatter

Bank of America downgraded Dr. Reddy's Laboratories (NYSE: RDY) from Buy to Neutral with a $36.72 price objective.

Bank of America noted, "Following recent outperformance (vs BSE Healthcare), we downgrade DRL from Buy to Neutral with a revised PO of Rs1975. This factors (1) higher mkt share from recent US launches, reflected in slight increase in core profit estimates, partially offset by (2) sharp cut in exclusivities driving reduction in NPV to Rs25 (vs Rs70 earlier). We expect multiples to be capped due to modest growth prospects (12% profit CAGR), below historic growth and peers."

Dr Reddy's Laboratories closed at $35.76 on Thursday.

Latest Ratings for RDY

DateFirmActionFromTo
Jul 2016HSBCDowngradesHoldReduce
Jul 2016JefferiesDowngradesHoldUnderperform
Jul 2016Credit SuisseDowngradesNeutralUnderweight

View More Analyst Ratings for RDY
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Downgrades Analyst Ratings

 

Related Articles (RDY)

View Comments and Join the Discussion!